H.C. Wainwright downgraded Tracon Pharmaceuticals to Neutral from Buy and removed the firm’s prior price target after the company announced that the objective response rate by blinded independent central review of 5%in the ENVASARC Phase 2 trial did not reach the primary endpoint. Following the results, the firm no longer includes envafolimab in its valuation, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TCON:
- TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
- TRACON Pharmaceuticals Announces Executive Officer Resignation
- Biotech Alert: Searches spiking for these stocks today
- Tracon Pharmaceuticals announces publication of Phae 2 data for TRC102
- TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue